DK1589976T3 - Anvendelse af en kombination af en aromatase-inhibitor, et progestin og et estrogen til behandling af endometriose - Google Patents

Anvendelse af en kombination af en aromatase-inhibitor, et progestin og et estrogen til behandling af endometriose

Info

Publication number
DK1589976T3
DK1589976T3 DK04707574T DK04707574T DK1589976T3 DK 1589976 T3 DK1589976 T3 DK 1589976T3 DK 04707574 T DK04707574 T DK 04707574T DK 04707574 T DK04707574 T DK 04707574T DK 1589976 T3 DK1589976 T3 DK 1589976T3
Authority
DK
Denmark
Prior art keywords
progestin
endometriosis
estrogen
treatment
combination
Prior art date
Application number
DK04707574T
Other languages
English (en)
Inventor
Stephen Rubin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1589976T3 publication Critical patent/DK1589976T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04707574T 2003-02-05 2004-02-03 Anvendelse af en kombination af en aromatase-inhibitor, et progestin og et estrogen til behandling af endometriose DK1589976T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0302572.3A GB0302572D0 (en) 2003-02-05 2003-02-05 Method of treatment
PCT/GB2004/000414 WO2004069260A1 (en) 2003-02-05 2004-02-03 Compositon comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis

Publications (1)

Publication Number Publication Date
DK1589976T3 true DK1589976T3 (da) 2007-12-27

Family

ID=9952433

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04707574T DK1589976T3 (da) 2003-02-05 2004-02-03 Anvendelse af en kombination af en aromatase-inhibitor, et progestin og et estrogen til behandling af endometriose

Country Status (30)

Country Link
US (2) US7910570B2 (da)
EP (2) EP1857111A3 (da)
JP (2) JP4658918B2 (da)
KR (1) KR101075929B1 (da)
CN (1) CN100393360C (da)
AR (1) AR043013A1 (da)
AT (1) ATE374612T1 (da)
AU (1) AU2004210184B2 (da)
BR (1) BRPI0407039A (da)
CA (1) CA2513910C (da)
CO (1) CO5580789A2 (da)
CY (1) CY1107816T1 (da)
DE (1) DE602004009288T2 (da)
DK (1) DK1589976T3 (da)
ES (1) ES2293215T3 (da)
GB (1) GB0302572D0 (da)
HK (1) HK1082918A1 (da)
IL (1) IL169583A0 (da)
IS (1) IS2547B (da)
MX (1) MXPA05008347A (da)
MY (1) MY140723A (da)
NO (1) NO20053626L (da)
NZ (1) NZ541222A (da)
PL (1) PL214680B1 (da)
PT (1) PT1589976E (da)
RU (2) RU2360681C2 (da)
TW (1) TWI354556B (da)
UA (1) UA80741C2 (da)
WO (1) WO2004069260A1 (da)
ZA (1) ZA200506221B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
CN101107004A (zh) * 2004-10-04 2008-01-16 韦恩州立大学 芳香酶抑制剂在子宫内膜腔和子宫手术前的子宫薄化中的应用
US20100292150A1 (en) * 2007-12-10 2010-11-18 Meditrina Pharmaceuticals, Inc. Treatment of Menorrhagia with Aromatase Inhibitor
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EP2476409A1 (en) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant comprising a core and a tube encasing the core
RU2541089C1 (ru) * 2013-11-22 2015-02-10 Федеральное государственное бюджетное учреждение "Научно-исследовательски институт акушерства и гинекологии им. Д.О. Отта" Северо-Западного отделения Российской академии медицинских наук Способ комплексного лечения наружного генитального эндометриоза
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
KR20240076617A (ko) 2022-11-22 2024-05-30 성균관대학교산학협력단 디프레닐로로볼을 유효성분으로 포함하는 자궁내막증 예방 또는 치료용 약제학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
ES2077675T3 (es) * 1989-03-10 1995-12-01 Endorecherche Inc Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos.
JP2602456B2 (ja) 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
NZ536787A (en) 1998-06-11 2006-03-31 Endorech Inc Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta diol
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US20040192598A1 (en) 2000-10-11 2004-09-30 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
PT1377298E (pt) 2001-01-26 2006-12-29 Pharmacia & Upjohn Co Llc Exemestano para o tratamento de perturbações hormono-dependentes.
AU2002240949A1 (en) 2001-03-21 2002-10-03 Schering Aktiengesellschaft Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy
GB0120147D0 (en) 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017973A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
CA2466106A1 (en) 2001-11-06 2003-05-15 Applied Research Systems Ars Holding N.V. Methods of treating endometreosis
KR20040073572A (ko) 2002-01-22 2004-08-19 악조 노벨 엔.브이. 내인성 에스트로겐의 합성을 예방하는 약물의 투여와관련된 호소 증상의 치료에서의 티볼론
WO2003082299A1 (en) * 2002-04-03 2003-10-09 Jencap Research Ltd. Improved hormone replacement therapy
US20040235812A1 (en) 2002-04-03 2004-11-25 Caspers Robert F Pharmaceutical composition comprisng an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
AU2003213958A1 (en) * 2002-04-03 2003-10-13 Jencap Research Ltd. Female birth control method
JP2006516084A (ja) * 2002-06-27 2006-06-22 セントカー・インコーポレーテツド Ｃｎｇｈ０００４ポリペプチド、抗体、組成物、方法および使用
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment

Also Published As

Publication number Publication date
EP1857111A3 (en) 2009-03-04
AU2004210184B2 (en) 2007-01-04
IS8008A (is) 2005-08-30
CO5580789A2 (es) 2005-11-30
DE602004009288T2 (de) 2008-07-10
CA2513910C (en) 2012-04-03
UA80741C2 (en) 2007-10-25
ES2293215T3 (es) 2008-03-16
BRPI0407039A (pt) 2006-01-17
CN1747736A (zh) 2006-03-15
KR20050098296A (ko) 2005-10-11
GB0302572D0 (en) 2003-03-12
DE602004009288D1 (de) 2007-11-15
EP1589976A1 (en) 2005-11-02
JP2006516602A (ja) 2006-07-06
RU2005127667A (ru) 2006-03-27
TW200503731A (en) 2005-02-01
PL214680B1 (pl) 2013-09-30
NZ541222A (en) 2008-12-24
RU2008138166A (ru) 2010-03-27
TWI354556B (en) 2011-12-21
CA2513910A1 (en) 2004-08-19
PT1589976E (pt) 2007-11-22
EP1589976B1 (en) 2007-10-03
US20060142256A1 (en) 2006-06-29
KR101075929B1 (ko) 2011-10-26
ATE374612T1 (de) 2007-10-15
CY1107816T1 (el) 2013-06-19
NO20053626L (no) 2005-08-26
PL377939A1 (pl) 2006-02-20
JP2011001388A (ja) 2011-01-06
ZA200506221B (en) 2006-05-31
HK1082918A1 (en) 2006-06-23
AR043013A1 (es) 2005-07-13
WO2004069260A1 (en) 2004-08-19
MXPA05008347A (es) 2005-11-04
IL169583A0 (en) 2007-07-04
RU2360681C2 (ru) 2009-07-10
US7910570B2 (en) 2011-03-22
CN100393360C (zh) 2008-06-11
EP1857111A2 (en) 2007-11-21
JP4658918B2 (ja) 2011-03-23
US20110009373A1 (en) 2011-01-13
AU2004210184A1 (en) 2004-08-19
MY140723A (en) 2010-01-15
IS2547B (is) 2009-10-15

Similar Documents

Publication Publication Date Title
DK1740197T3 (da) Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki
DK1713503T3 (da) Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
NO20054133D0 (no) Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor
NL1026490A1 (nl) Instructiesetextensie onder gebruikmaking van 3-byte escape opcode.
DE50307239D1 (de) Ausschleuseinrichtung
DE60311032D1 (de) Wandlervorrichtung
NO20025188L (no) Anordning ved elektroniske apparater og utstyr
HK1082918A1 (en) Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis
DK1623711T3 (da) Eksternt plaster indeholdende östrogen og/eller progestogen
DK1457208T3 (da) Fremgangsmåde og farmaceutiske præparater til pålidelig opnåelse af acceptable serumtestosteronniveauer
DK1404148T3 (da) Indretning og fremgangsmåde til styring af tilbagekobling
DK1509990T3 (da) Konfiguration og fremgangsmåde til beskyttelse af omformerorganer
DE60207518D1 (de) Dämpfungseinrichtung
DE60215882D1 (de) Handeingabevorrichtung
DK1626736T3 (da) C1-inhibitor med kort halveringstid til midlertidig behandling
DE50308833D1 (de) Eingabevorrichtung
IS7694A (is) Sterasamrunaefnasambönd, framleiðsla og notkun þeirra
DE60321641D1 (de) Photopolymerisierbare Initiatorkombination und photopolymerisierbare Zusammensetzung
DK1638617T3 (da) Efterudladningsplasmasterilisationsindretning
DE602004018921D1 (de) D dienogest
DK1504211T3 (da) Indretning til at forbinde rörledninger
SI1589976T1 (sl) Uporaba kombinacije aromataznega inhibitorja, progestina in estrogena za zdravljenje endometrioze
EP1638573A4 (en) USE OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS
DE60314023D1 (de) Handbetätigte eingabevorrichtung
ATA15642003A (de) Orthopädische liege